Search

Your search keyword '"Zhu, A.X."' showing total 6 results
Start Over Author "Zhu, A.X." Publication Year Range Last 3 years
6 results on '"Zhu, A.X."'

1. NRG/RTOG 1112: Randomized Phase III Study of Sorafenib vs. Stereotactic Body Radiation Therapy (SBRT) Followed by Sorafenib in Hepatocellular Carcinoma (HCC) (NCT01730937)

Author

Dawson, L.A., primary, Winter, K., additional, Knox, J., additional, Zhu, A.X., additional, Krishnan, S., additional, Guha, C., additional, Kachnic, L.A., additional, Gillin, M.T., additional, Hong, T.S., additional, Craig, T., additional, Hosni, A., additional, Chen, E., additional, Noonan, A., additional, Koay, E.J., additional, Sinha, R., additional, Lock, M.I., additional, Ohri, N., additional, Dorth, J.A., additional, Moughan, J., additional, and Crane, C.H., additional

Published
2022
Full Text
View/download PDF

2. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer

Author

Berchuck, J.E., primary, Facchinetti, F., additional, DiToro, D.F., additional, Baiev, I., additional, Majeed, U., additional, Reyes, S., additional, Chen, C., additional, Zhang, K., additional, Sharman, R., additional, Uson Junior, P.L.S., additional, Maurer, J., additional, Shroff, R.T., additional, Pritchard, C.C., additional, Wu, M.-J., additional, Catenacci, D.V.T., additional, Javle, M., additional, Friboulet, L., additional, Hollebecque, A., additional, Bardeesy, N., additional, Zhu, A.X., additional, Lennerz, J.K., additional, Tan, B., additional, Borad, M., additional, Parikh, A.R., additional, Kiedrowski, L.A., additional, Kelley, R.K., additional, Mody, K., additional, Juric, D., additional, and Goyal, L., additional

Published
2022
Full Text
View/download PDF

3. Long-Term Results of a Multi-Institutional Phase II Study of Hypofractionated Proton Beam Irradiation of Unresectable Primary Liver Tumors

Author

Roberts, H.J., primary, Hong, T.S., additional, Ly, L., additional, Yeap, B.Y., additional, Ben-Josef, E., additional, Zhu, A.X., additional, Goyal, L., additional, Franses, J., additional, Ryan, D.P., additional, Allen, J.N., additional, Clark, J.W., additional, Drapek, L.C., additional, Tanabe, K., additional, Ferrone, C.R., additional, Koay, E.J., additional, Crane, C.H., additional, DeLaney, T.F., additional, and Wo, J.Y., additional

Published
2022
Full Text
View/download PDF

4. LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma

Author

Qin, S., primary, Kudo, M., additional, Meyer, T., additional, Finn, R.S., additional, Vogel, A., additional, Bai, Y., additional, Guo, Y., additional, Meng, Z., additional, Zhang, T., additional, Satoh, T., additional, Hiraoka, A., additional, Marino, D., additional, Assenat, E., additional, Wyrwicz, L., additional, Campos, M. Calvo, additional, Hsing-Tao, K., additional, Boisserie, F., additional, Li, S., additional, Chen, Y., additional, and Zhu, A.X., additional

Published
2022
Full Text
View/download PDF

5. VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial

Author

Kelley, R.K., primary, Yau, T., additional, Cheng, A.-L., additional, Kaseb, A., additional, Qin, S., additional, Zhu, A.X., additional, Chan, S., additional, Sukeepaisarnjaroen, W., additional, Breder, V., additional, Verset, G., additional, Gane, E., additional, Borbath, I., additional, Gomez Rangel, J.D., additional, Merle, P., additional, Benzaghou, F.M., additional, Banerjee, K., additional, Hazra, S., additional, Fawcett, J., additional, and Rimassa, L., additional

Published
2022
Full Text
View/download PDF

6. Alpha-fetoprotein as a potential surrogate biomarker for atezolizumab + bevacizumab treatment of hepatocellular carcinoma

Author

Zhu, A.X. (Andrew X.)

Subjects
Atezolizumab, Bevacizumab, Alpha-fetoprotein (AFP), Hepatocellular carcinoma (HCC)
Abstract

Purpose: Atezolizumab + bevacizumab is the new standard of care for systemic treatment-naïve, unresectable hepatocellular carcinoma (HCC). This exploratory study investigated on-treatment alpha-fetoprotein (AFP) response as a potential surrogate biomarker of prognosis for the combination therapy. Experimental design: Data from Group A of the phase Ib GO30140 study were used to identify the optimal time for AFP measurement and AFP cutoffs to differentiate patients by their best confirmed response per independent review facility-assessed RECIST (IRF-RECIST) version 1.1: responders from nonresponders and patients with disease control from primary progressors. We applied these cutoffs to independent data from the atezolizumab + bevacizumab arm of the phase III IMbrave150 trial to distinguish patients based on (i) overall survival (OS) and progression-free survival (PFS) per IRF-RECIST 1.1 and (ii) best confirmed response per IRF-RECIST 1.1. Results: We derived AFP cutoffs of ≥75% decrease and ≤10% increase from baseline at 6 weeks to identify responders and those who had disease control, respectively. These cutoffs had high sensitivity and specificity in GO30140. In IMbrave150 patients, sensitivity was 0.59 and specificity was 0.86 for the ≥75% decrease AFP cutoff; the sensitivity was 0.77 and specificity was 0.44 for the ≤10% increase AFP cutoff. Both AFP cutoffs were associated with longer OS and PFS, particularly in patients with hepatitis B virus etiology (HR < 0.5; P < 0.01). Conclusions: AFP response at 6 weeks after initiating treatment is a potential surrogate biomarker of prognosis for patients with HCC receiving atezolizumab + bevacizumab. See related commentary by Cappuyns and Llovet, p. 3405.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results